Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.67 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262126 | 0.88 | OPRD1 (0.51) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL471296 | 0.87 | OPRD1 (0.66) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL471297 | 0.87 | OPRD1 (0.61) | OPRD1KCNH2CYP2D6OPRK1GPR119 | |
| SCHEMBL10258475 | 0.86 | OPRD1 (0.59) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL10258347 | 0.86 | OPRD1 (0.62) | OPRD1KCNH2CYP2D6OPRK1GPR119 | |
| SCHEMBL12265335 | 0.86 | OPRD1 (0.77) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL12482065 | 0.86 | OPRD1 (0.54) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL3696965 | 0.85 | OPRD1 (0.54) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL12050479 | 0.85 | OPRD1 (0.54) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL471710 | 0.85 | OPRD1 (0.55) | OPRD1KCNH2CYP2D6OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-8071611-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100222374-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-09-02 | — | — | US | disclosed |
| US-7638527-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222374-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885CYP2D6 138/4885 |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885CYP2D6 138/4885 |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | OPRD1 2/4885KCNH2 1285/4885CYP2D6 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.